Olanzapine: a full and potent agonist at the hM4D(Gi) DREADD amenable to clinical translation of chemogenetics
Mikail Weston, Teresa Kaserer, Angela J. Wu, Alexandre Mouravlev, Jenna C. Carpenter, Albert Snowball, Samuel Knauß, Melanie J. von Schimmelmann, Matthew J. During, Gabriele Lignani, Stéphanie Schorge, Deborah Young, Dimitri Michael Kullmann, Andreas Lieb
The paper identifies olanzapine as a potent and full agonist for the hM4D(Gi) DREADD, enabling clinical translation of chemogenetics for CNS diseases.
Science Advances · Apr 5, 2019Peer-reviewedNeuroscience